Login to Your Account

Clinic Roundup

Tuesday, May 31, 2011
• UCB SA, of Brussels, Belgium, reported data showing that the addition of Cimzia (certolizumab pegol) to current therapy was associated with a rapid and consistent clinical response in a diverse group of rheumatoid arthritis patients. Consistent efficacy was observed across patients taking the drug, whether they had previously received TNF inhibitors or not and whether they received Cimzia monotherapy or with concomitant disease-modifying antirheumatic drugs. Those results were presented at the European League Against Rheumatism meeting in London.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription